GLP1R and obesity due to melanocortin 4 receptor deficiency: Recently, the development of GLP-1 agonists that show promise against obesity-associated disease named as Science’s 2023 Breakthrough (https://www.science.org/content/article/breakthrough-of-the-year-2023).